Adjuvax LLC focuses on developing novel saponin-based vaccine adjuvants as a practical alternative to the well-established and FDA-approved saponin adjuvant QS-21.

Our Technology

Adjuvants constitute an indispensable element of modern vaccines because they enhance the ability of a vaccine to elicit strong and durable immune responses (including in immunologically compromised individuals), reduce the required antigen dose and number of immunizations, and modulate the immune response for a specific pathogen.

Read More